The Complexities of Treating Rosacea, with Benjamin Ungar, MD

March 12th 2025

Breakthroughs in Atopic Dermatitis with Linda Stein Gold, MD: Primary Viewpoints Podcast

The impact of childhood onset AD on adult psychosocial experience, including employment and the decision to become a parent, is profound, this study reveals.

Linda Stein Gold, MD;Sydney Jennings

Delgocitinib Data Reveal "Super Responders" in CHE During AAD 2025 Late Breaker

Podcast

“I think it’s important to have a lot of tools in our toolbox, and [tapinarof cream 1%] is one that gives us great flexibility," said Linda Stein Gold, MD.

Zabalafin Hydrogel Shows Efficacy in Atopic Dermatitis, Including Cases with Bacterial Infection

Data on delgocitinib from the DELTA development program highlight efficacy of the topical JAK inhibitor for treatment of chronic hand eczema.

Patient Care Editorial Staff

Rocatinlimab, an OX40 Inhibitor, Achieves Positive Results in Atopic Dermatitis Treatment: ROCKET-Horizon Topline Findings

Data on Zabalafin Hydrogel topical therapy may offer a single, comprehensive approach to manage AD across multiple disease stages.

Atopic Dermatitis Breakthrough: Linda Stein Gold, MD, on Tapinarof's Treatment-Free Benefits

Approximately one-third of participants treated with rocatinlimab achieved EASI-75 at 24 weeks, more than 2 times the proportion in the placebo group, among other robust findings.

Sydney Jennings

Atopic Dermatitis of Childhood Onset Significantly Impacts "Life Trajectory" According to Scars of Life Survey

AAD 2025. Linda Stein Gold, MD, FAAD, discusses the late-breaking tapinarof cream 1% data from a new analysis of the ADORING-3 clinical trial.

Related Content

March 12th 2025

Breakthroughs in Atopic Dermatitis with Linda Stein Gold, MD: Primary Viewpoints Podcast

The impact of childhood onset AD on adult psychosocial experience, including employment and the decision to become a parent, is profound, this study reveals.

Linda Stein Gold, MD;Sydney Jennings

Delgocitinib Data Reveal "Super Responders" in CHE During AAD 2025 Late Breaker

Podcast

“I think it’s important to have a lot of tools in our toolbox, and [tapinarof cream 1%] is one that gives us great flexibility," said Linda Stein Gold, MD.

Zabalafin Hydrogel Shows Efficacy in Atopic Dermatitis, Including Cases with Bacterial Infection

Data on delgocitinib from the DELTA development program highlight efficacy of the topical JAK inhibitor for treatment of chronic hand eczema.

Patient Care Editorial Staff

Rocatinlimab, an OX40 Inhibitor, Achieves Positive Results in Atopic Dermatitis Treatment: ROCKET-Horizon Topline Findings

Data on Zabalafin Hydrogel topical therapy may offer a single, comprehensive approach to manage AD across multiple disease stages.

Atopic Dermatitis Breakthrough: Linda Stein Gold, MD, on Tapinarof's Treatment-Free Benefits

Approximately one-third of participants treated with rocatinlimab achieved EASI-75 at 24 weeks, more than 2 times the proportion in the placebo group, among other robust findings.

Sydney Jennings